Published in J Negat Results Biomed on January 05, 2012
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev (1995) 13.66
Principles of CDK regulation. Nature (1995) 13.09
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell (1994) 9.25
The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta (1998) 4.45
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst (1998) 2.39
Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res (1995) 2.11
Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol (1998) 2.07
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res (2003) 1.96
Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res (1998) 1.70
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst (1999) 1.63
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl (2005) 1.54
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
Role of p21(WAF1) and p27(KIP1) in predicting biochemical recurrence for organ-confined prostate adenocarcinoma. J Chin Med Assoc (2007) 1.43
Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression. Mol Cell Biol (1998) 1.35
Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst (1998) 1.28
Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res (2003) 1.19
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res (1999) 1.07
Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol (1998) 1.04
Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol (2006) 1.02
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res (2001) 1.02
Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch (2004) 1.00
Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res (2004) 0.97
Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol (1999) 0.91
Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol (1999) 0.90
Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res (2003) 0.90
p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo (2005) 0.89
Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer (1999) 0.88
Immunohistochemistry expression of tumor markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy. Rev Col Bras Cir (2010) 0.86
Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer (2000) 0.85
Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol Rep (2001) 0.84
Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells. Int Urol Nephrol (2008) 0.82
Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Anticancer Res (2004) 0.77
Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. Urol Oncol (2011) 0.77
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol (2003) 2.29
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr (2010) 1.76
Fine needle aspiration cytology of a primary malignant peripheral nerve sheath tumor arising in the parotid gland: a case report. Acta Cytol (2009) 1.39
Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. Int J Cancer (2007) 1.35
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer (2012) 1.30
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol (2003) 1.27
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl) (2011) 1.13
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol (2002) 1.06
Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness. Arch Pathol Lab Med (2008) 0.95
Beyond anorexia -cachexia. Nutrition and modulation of cancer patients' metabolism: supplementary, complementary or alternative anti-neoplastic therapy? Eur J Pharmacol (2011) 0.95
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer (2011) 0.95
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int (2009) 0.94
Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. Support Care Cancer (2011) 0.91
Tubulointerstitial nephritis and uveitis (TINU) syndrome in a 52-year-old female: a case report and review of the literature. Ren Fail (2006) 0.90
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation. J Cell Mol Med (2009) 0.90
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res (2011) 0.89
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2006) 0.88
Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int (2011) 0.88
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate (2007) 0.87
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation. J Cell Mol Med (2009) 0.86
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer (2002) 0.85
Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men. Cancer Epidemiol (2010) 0.84
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance. Urol Oncol (2010) 0.84
Rapid fatal outcome from pulmonary arteries compression in transitional cell carcinoma. J Oncol (2010) 0.84
CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy. Urol Int (2012) 0.84
The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis? J Cell Commun Signal (2013) 0.83
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer (2003) 0.83
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res (2004) 0.83
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int J Colorectal Dis (2010) 0.82
Bortezomib downregulates MGMT expression in T98G glioblastoma cells. Cell Mol Neurobiol (2013) 0.82
Bladder stone formation after a tension-free vaginal tape procedure: report on two cases. Urol Int (2007) 0.82
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Int J Urol (2012) 0.81
Orbital metastasis of breast carcinoma. Breast Cancer (Auckl) (2009) 0.81
Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol (2006) 0.80
Bone and brain metastases from ampullary adenocarcinoma. World J Gastroenterol (2009) 0.80
INCENP (inner centromere protein) is overexpressed in high grade non-Hodgkin B-cell lymphomas. Pathol Oncol Res (2008) 0.80
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma. Cell Biol Toxicol (2013) 0.79
The role of ubiquitin-proteasome system in glioma survival and growth. Growth Factors (2013) 0.79
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs (2013) 0.79
Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. Nutr Cancer (2011) 0.79
The ubiquitin-proteasome system in glioma cell cycle control. Cell Div (2012) 0.79
Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer Chemother Pharmacol (2010) 0.78
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53. Neurol Res (2013) 0.78
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab. BMC Nephrol (2011) 0.77
CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases. Clin Dev Immunol (2013) 0.77
AFP-producing hepatoid adenocarcinoma of the stomach: a case report. Cases J (2009) 0.77
Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells. Cancer Cell Int (2012) 0.76
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer (2010) 0.76
p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer. Pathol Oncol Res (2011) 0.75
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy. Prostate Cancer (2012) 0.75
Selecting for predisposition to cancer cachexia. EMBO Mol Med (2012) 0.75
Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle-invasive bladder cancer. Tumour Biol (2015) 0.75
Erratum to: Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle-invasive bladder cancer. Tumour Biol (2015) 0.75
The shaping of invasive glioma phenotype by the ubiquitin-proteasome system. Cell Commun Adhes (2013) 0.75
Urodynamics prior to renal transplantation--its impact on treatment decision and final results. Scand J Urol Nephrol (2003) 0.75
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol (2003) 0.75
A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors. Oncology (2007) 0.75
The effectiveness of a scientific symposium to change urologists' attitude towards treatment of LUTS/BPH. Int Urol Nephrol (2007) 0.75
Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer. Onkologie (2010) 0.75